NEW YORK, January 2, 2026, 20:02 ET — Market closed
Thermo Fisher Scientific Inc (NYSE: TMO) shares rose 2.25% to $592.51 on Friday, outpacing the S&P 500’s 0.19% gain in the first session of 2026. The stock finished about 3% below its 52-week high of $610.97, and trading volume of roughly 2.1 million shares ran above its 50-day average of about 1.7 million.
The outperformance came as Wall Street steadied after a late-December slide, with the Dow and S&P 500 ending higher and snapping a four-day losing streak, Reuters reported. “The market is seeing a ‘buy the dip, sell the rip,’ trading mentality,” Joe Mazzola, head of trading & derivatives strategist at Charles Schwab, told Reuters. Reuters
“Buy the dip, sell the rip” is trader shorthand for buying pullbacks and trimming positions into sharp rallies, aiming to profit from short-term swings rather than commit at peak prices. That mindset has been in focus after stocks failed to deliver a typical “Santa Claus rally,” the seasonal late-December and early-January boost investors often cite.
For Thermo Fisher, the early-year bid keeps attention on whether investors are willing to pay up for large-cap life science tools names as the market debates valuations. The company sits at the crossroads of drug development, diagnostics and lab spending, areas that can shift quickly with financing conditions and research budgets.
Peers moved higher too. Danaher gained 0.65% and Agilent Technologies rose 1.38% in Friday’s session, offering a supportive read-through for the broader tools and diagnostics group.
The sector’s sensitivity to interest-rate expectations can amplify stock moves early in the year, when positioning tends to reset. Shifts in macro data can also hit sentiment fast, particularly for companies where investors are paying for steady cash flow and mid-term growth.
Thermo Fisher has a clear company-specific checkpoint later this month. The company said it will release fourth-quarter and full-year 2025 results before the market opens on Thursday, Jan. 29, and host a conference call at 8:30 a.m. ET.
Traders are likely to use that report to judge the pace of demand across lab products, biotech and pharma services, and any changes in order trends. Guidance will matter as much as the quarter, especially any commentary on customer spending discipline and the outlook for 2026.
Before the next session on Monday, investors will be watching whether Friday’s rebound holds as liquidity returns after the weekend. Markets can remain headline-sensitive at the start of the year, and even stocks with no fresh company news can move sharply on risk appetite.
Technically, Thermo Fisher traded between $579 and $594 on Friday after opening around $579.50. That leaves the low-$580s area as a near-term level traders may watch if the stock gives back gains, while a renewed push toward prior highs would signal momentum is still building.
For now, Thermo Fisher ends the week with a bounce that puts the focus back on fundamentals rather than year-end positioning. The next major catalyst is the Jan. 29 earnings release, with macro data in between likely to shape how investors price the company’s 2026 setup.
